Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
AstraZeneca
Dow
Express Scripts
Baxter
US Department of Justice
McKesson
Chinese Patent Office
Harvard Business School

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203108

« Back to Dashboard

NDA 203108 describes STRIVERDI RESPIMAT, which is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are eighteen patents protecting this drug. Additional details are available on the STRIVERDI RESPIMAT profile page.

The generic ingredient in STRIVERDI RESPIMAT is olodaterol hydrochloride. One supplier is listed for this compound. Additional details are available on the olodaterol hydrochloride profile page.
Summary for 203108
Tradename:STRIVERDI RESPIMAT
Applicant:Boehringer Ingelheim
Ingredient:olodaterol hydrochloride
Patents:18
Pharmacology for NDA: 203108
Mechanism of ActionAdrenergic beta2-Agonists
Suppliers and Packaging for NDA: 203108
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0192 N 0597-0192-61

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;INHALATIONStrengthEQ 0.0025MG BASE/INH
Approval Date:Jul 31, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 31, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Sign UpPatent Expiration:Aug 28, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Aug 28, 2018Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 203108

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108-001 Jul 31, 2014 ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108-001 Jul 31, 2014 ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108-001 Jul 31, 2014 ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108-001 Jul 31, 2014 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
McKesson
Express Scripts
Queensland Health
Deloitte
Johnson and Johnson
US Army
Accenture
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.